» Articles » PMID: 35833023

Psychedelic Therapies at the Crossroads of Trauma and Substance Use: Historical Perspectives and Future Directions, Taking a Lead From New Mexico

Overview
Journal Front Pharmacol
Date 2022 Jul 14
PMID 35833023
Authors
Affiliations
Soon will be listed here.
Abstract

Post-traumatic stress disorder (PTSD), a common condition with potentially devastating individual, family, and societal consequences, is highly associated with substance use disorders (SUDs). The association between PTSD and SUD is complex and may involve adverse childhood experiences (ACEs), historical and multi-generational traumas, and social determinants of health as well as cultural and spiritual contexts. Current psychosocial and pharmacological treatments for PTSD are only modestly effective, and there is a need for more research on therapeutic interventions for co-occurring PTSD and SUD, including whether to provide integrated or sequential treatments. There is a current resurgence of interest in psychedelics as potential treatment augmentation for PTSD and SUDs with an appreciation of the risks in this target population. This paper reviews the historical perspective of psychedelic research and practices, as well as the intersection of historical trauma, ACEs, PTSD, and SUDs through the lens of New Mexico. New Mexico is a state with high populations of Indigenous and Hispanic peoples as well as high rates of trauma, PTSD, and SUDs. Researchers in New Mexico have been leaders in psychedelic research. Future directions for psychedelic researchers to consider are discussed, including the importance of community-based participatory approaches that are more inclusive and respectful of Indigenous and other minority communities.

Citing Articles

Treatment patterns and characteristics of patients with Post-Traumatic Stress Disorder (PTSD): A retrospective claims analysis among commercially insured population.

Stanicic F, Zah V, Grbic D, Angelo D, Bibeau W PLoS One. 2024; 19(10):e0309704.

PMID: 39475900 PMC: 11524461. DOI: 10.1371/journal.pone.0309704.


Lifeboat ethics, risk, and therapeutic opportunity: an appeal for equitable psychedelic therapy access in the "high-risk" addiction patient.

Black T Front Psychiatry. 2023; 14:1159843.

PMID: 37799400 PMC: 10548230. DOI: 10.3389/fpsyt.2023.1159843.

References
1.
Strassman R . Human psychopharmacology of N,N-dimethyltryptamine. Behav Brain Res. 1996; 73(1-2):121-4. DOI: 10.1016/0166-4328(96)00081-2. View

2.
HOFFMEISTER F . Negative reinforcing properties of some psychotropic drugs in drug-naive rhesus monkeys. J Pharmacol Exp Ther. 1975; 192(2):468-77. View

3.
Halpern J, Sherwood A, Hudson J, Yurgelun-Todd D, Pope Jr H . Psychological and cognitive effects of long-term peyote use among Native Americans. Biol Psychiatry. 2005; 58(8):624-31. DOI: 10.1016/j.biopsych.2005.06.038. View

4.
Greenfield B, Venner K . Review of substance use disorder treatment research in Indian country: future directions to strive toward health equity. Am J Drug Alcohol Abuse. 2012; 38(5):483-92. DOI: 10.3109/00952990.2012.702170. View

5.
Venner K, Donovan D, Campbell A, Wendt D, Rieckmann T, Radin S . Future directions for medication assisted treatment for opioid use disorder with American Indian/Alaska Natives. Addict Behav. 2018; 86:111-117. PMC: 6129390. DOI: 10.1016/j.addbeh.2018.05.017. View